KEYTRUDA
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
An experimental lung-cancer drug could replace Keytruda one day. But investors aren’t wowed.
The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug
Could cancer vaccines be next? New treatment cuts melanoma risk by nearly 50%
A new injectable therapy is showing positive results in reducing melanoma throughout a five-year period. The personalized mRNA cancer therapy, called intismeran autogene, combined with the cancer immunotherapy drug KEYTRUDA (pembrolizumab), is a collaboration between Merck and Moderna. The results from the phase 2b KEYNOTE-942 study were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on May 27.CLICK HERE FOR MORE HEALTH STORIESAfter about a five-year...
A cancer vaccine made just for you. mRNA is back and it's fighting melanoma
A study finds that an mRNA vaccine is highly effective at preventing recurrence of this dangerous skin cancer, when used in combination with Keytruda, an immunotherapy drug.
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a closely watched late-stage trial, according to results released Sunday. When combined with chemotherapy, the drug kept people with squamous non-small-cell lung cancer alive for a median of four months longer than the standard combination of immunotherapy and chemotherapy, a result that was statistically significant, according to an abstract released Sunday ahead of a presentation at the...
A personalized vaccine for melanoma cut the risk of cancer returning after five years
An experimental vaccine from Moderna shows promise in keeping deadly skin cancer from returning for years, according to new clinical trial results. The research, presented Monday at the American Society of Clinical Oncology’s annual meeting, found that a personalized mRNA vaccine halved the risk of melanoma returning after five years. The results were also published in the Journal of Clinical Oncology.
The space race is coming for pharma: Why drug development is heading to lower Earth orbit
The highly anticipated SpaceX mega-IPO is part of a space frenzy that is moving beyond satellite connectivity, launch vehicles, and aerospace defense to the pharmaceutical sector. A growing number of companies are heading to lower Earth orbit to make medicines in microgravity. The range of commercial opportunities is expanding as foundational aerospace industries set the necessary infrastructure.
GLP-1 drugs, including Ozempic, may have a beneficial effect across many types of cancer
GLP-1 drugs, including Ozempic, may have a beneficial effect across many types of cancer More than two dozen studies suggest the treatments are linked to lower cancer risk, reduced metastasis and improved survival, though researchers say trials are needed to confirm any anti-cancer benefit. A growing body of evidence suggests that popular GLP-1 drugs, widely used for weight loss and diabetes, can provide protection against many types of cancer. More than two dozen studies presented over the...